SuperworthUroGen Pharma price to sales ratio URGN
Market value divided by revenue over the last twelve months, since 2021.
- Today, Oct 23, 2026
- 8.9×
- 5-year median
- 6.0×
- Against its 5-year history
- 70th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 2.1× to 21.4×
- Peer median
- 2.0×
UroGen Pharma's price to sales ratio is 8.9× as of Oct 23, 2026.
That is above its 5-year median of 6.0×, higher than on 70% of days in the last 5 years.
Over that time it ranged from 2.1× in May 2025 to 21.4× in May 2021.
The median for 10 large drugmakers of a similar size is 2.0×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 8.9× | 7.6× | 14.2× |
| 2025 | 11.2× | 2.1× | 14.0× |
| 2024 | 5.1× | 5.0× | 8.2× |
| 2023 | 6.0× | 3.0× | 9.3× |
| 2022 | 3.3× | 2.3× | 5.1× |
| 2021 | 5.4× | 5.3× | 21.4× |
Against its peers
Companies in Drug Manufacturers - General nearest UroGen Pharma's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| URGNUroGen Pharma | 8.9× |
| ANIPANI Pharmaceuticals | 1.7× |
| PAHCPhibro Animal Health | 1.0× |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 1.9× |
| HRMYHarmony Biosciences | 2.2× |
| PBHPrestige Consumer Healthcare | 2.0× |
| OMEROmeros | n/m |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| NRIXNurix Therapeutics | 3.9× |
| ABUSArbutus Biopharma | 4.6× |
| Peer median | 2.0× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on UroGen Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.